Walleye Capital
FOLD

Walleye Capital’s Amicus Therapeutics FOLD Stock Holding History

Walleye Capital’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,500
Closed -$78.3K – 4590
2025
Q4 		$78.3K Sell
5,500
-16,600
-75% -$163K ﹤0.01% 3952
2025
Q3 		$174K Buy
22,100
+6,900
+45% +$49.1K ﹤0.01% 3410
2025
Q2 		$87.1K Buy
+15,200
New +$98.1K ﹤0.01% 3836
2025
Q1 		– Sell
-18,600
Closed -$175K – 4524
2024
Q4 		$175K Sell
18,600
-16,000
-46% -$166K ﹤0.01% 3849
2024
Q3 		$370K Buy
34,600
+19,000
+122% +$207K ﹤0.01% 3570
2024
Q2 		$155K Buy
15,600
+1,100
+8% +$11.3K ﹤0.01% 4469
2024
Q1 		$171K Buy
+14,500
New +$185K ﹤0.01% 4075
2023
Q4 		– Sell
-600
Closed -$7.3K – 5134
2023
Q3 		$7.3K Buy
+600
New +$7.74K ﹤0.01% 4529
2019
Q3 		– Sell
-2,400
Closed -$30K – 2013
2019
Q2 		$30K Sell
2,400
-6,500
-73% -$82.5K ﹤0.01% 1471
2019
Q1 		$121K Buy
+8,900
New +$109K 0.02% 979

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Walleye Capital's FOLD Position: Q1 2026 in Review

Walleye Capital reduced its Amicus Therapeutics (FOLD) stake by 41% in Q1 2026, selling an estimated $152K and leaving 15,399 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #3275.

Walleye Capital first reported a position in FOLD in Q1 2019 and has held it in 12 quarters since. The position peaked at $4.32M in Q3 2024. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Walleye Capital held 15,399 shares of Amicus Therapeutics worth $223K as of Q1 2026.
  • Walleye Capital sold 10,631 Amicus Therapeutics shares in Q1 2026, an estimated $152K.
  • Amicus Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3275 holding.
  • Walleye Capital first reported a position in Amicus Therapeutics in Q1 2019 and has held it in 12 quarters since.
  • Walleye Capital's Amicus Therapeutics position peaked at $4.32M in Q3 2024.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.